Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Thalidomide Stories

2006-06-04 09:36:46

ATLANTA (Reuters) - Celgene Inc. said on Sunday its cancer drug Thalomid improved survival by a significant amount in elderly patients with multiple myeloma, a form of blood cancer. Data presented at the annual meeting of the American Society of Clinical Oncology in Atlanta showed that giving Thalomid in combination with two standard drugs improved survival compared with either the standard therapy alone or standard therapy plus a stem cell transplant. The current standard first-line...

2006-04-13 10:44:37

NEW YORK (Reuters Health) - Treatment with thalidomide or its analog lenalidomide prolongs life in mice with amyotrophic lateral sclerosis (ALS), scientists report. Lead investigator Dr. Mahmoud Kiaei told Reuters Health that small clinical trials are already underway in the US and in Germany "and we hope to set up a larger clinical trial in New York to examine the efficacy of these drugs in ALS patients." ALS, also known as Lou Gehrig's disease, is an incurable progressive...

2006-01-09 09:03:39

SAN FRANCISCO (Reuters) - Celgene Corp. said on Monday that a pivotal-stage trial of its Thalomid drug was stopped early after the medicine was shown to dramatically limit the progress of the blood cancer multiple myeloma. The drug, also known as thalidomide, was first introduced in the 1950s and became notorious for causing birth defects. It is currently approved for treating a symptom of leprosy. The Phase 3 trial of 270 patients found that that it took an average of 75.7 weeks for...

2006-01-09 07:44:20

SAN FRANCISCO (Reuters) - Celgene Corp. said on Monday that a pivotal-stage trial of its Thalomid drug was stopped early after the medicine was shown to dramatically limit the progress of the blood cancer multiple myeloma. The drug, also known as thalidomide, was first introduced in the 1950s and became notorious for causing birth defects. It is currently approved for treating a symptom of leprosy. The Phase 3 trial of 270 patients found that that it took an average of 75.7 weeks for...

2005-09-28 00:01:10

NEW YORK (Reuters) - A clinical trial of Celgene Corp.'s experimental cancer drug, Revlimid, has been suspended because of concerns about blood clots, the Wall Street Journal reported on Wednesday. The suspension comes as the company was awaiting notice from the Food and Drug Administration (FDA) next week on approval of the medicine, the newspaper said. It quoted the principal investigator in the study, S.V. Rajkumar, an oncologist at the Mayo Clinic, as saying he could not comment...

2005-09-14 17:36:27

By Susan Heavey BETHESDA, Maryland (Reuters) - Celgene Corp.'s Revlimid is effective in treating anemia in certain patients with potentially fatal blood disorders known as myelodysplastic syndromes and should be approved, a U.S. advisory panel said on Wednesday. The drug is a new version of Celgene's Thalomid or thalidomide, often remembered for tragic birth defects when used as a sedative in pregnant women but now finding new uses, such as for the blood cancer multiple myeloma. In...

2005-06-20 16:50:00

When people hear "thalidomide," many think "birth defects," however, evidence has come to light that this once-banned drug can be used as a potent anti-cancer treatment. In a new study, researchers from the University of Bologna, Italy, demonstrate that Thal-Dex (thalidomide used in combination with dexamethasone) is more powerful than conventional chemotherapy for the treatment of multiple myeloma. Their findings will be published in the July 1, 2005, issue of Blood, the official journal of...

2004-12-01 09:00:08

WARREN, N.J., Dec. 1 /PRNewswire-FirstCall/ -- Celgene Corporation announced today that clinical investigators from leading cancer research centers will present data from recent and on-going clinical trials of REVLIMID in multiple myeloma, myelodysplastic syndromes, other malignant blood disorders, as well as its mechanism of action at the American Society of Hematology 46TH Annual Meeting, one of the largest oncology meetings in the world, in San Diego, CA from December 2-7, 2004. The...